Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio (Nasdaq: ZURA) has commenced an underwritten public offering of Class A ordinary shares and, for certain investors, pre-funded warrants to buy Class A shares. The underwriters have a 30-day option to purchase up to 15% additional shares and shares underlying warrants. The offering is subject to market conditions and may not be completed as proposed. The securities will be offered pursuant to an existing Form S-3 shelf registration (No. 333-281905), declared effective September 17, 2024; a prospectus supplement will be filed with the SEC.
Zura Bio (Nasdaq: ZURA) appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. Neil Graham will step down from the Board effective the same date.
The additions bring senior immunology and clinical development experience, including prior roles at Vir Biotechnology, Genentech/Roche, Eli Lilly, and oversight of tibulizumab development.
Zura Bio (Nasdaq: ZURA) will participate in the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 11:00 AM ET in New York.
The senior leadership team will take part in a fireside chat and hold one-on-one investor meetings that same day. According to the company, a live webcast will be available in Investors > News & Events, with a replay archived for at least 30 days.
Zura Bio (Nasdaq: ZURA) named Sandeep Kulkarni, M.D. as Chief Executive Officer effective January 21, 2026; he will remain a Director. The company also announced the resignation of CEO Robert Lisicki, effective January 21, 2026, and that Kim Davis will continue as Chief Operating Officer, Chief Legal Officer, and Corporate Secretary. Dr. Kulkarni co-founded and led Tourmaline Bio through its acquisition by Novartis, which closed in October 2025. Zura highlighted two potentially transformative readouts expected over the next 18 months and emphasized tibulizumab as a lead bispecific program targeting IL-17 and BAFF.
Zura Bio (Nasdaq: ZURA) provided 2026 business updates and an outlook focused on tibulizumab, a bispecific antibody targeting IL-17 and BAFF for hidradenitis suppurativa (HS) and systemic sclerosis (SSc).
Key developments: the Phase 2 TibuSHIELD HS trial is expanding enrollment to 225 participants (from 180) with topline data now expected in Q4 2026. The Phase 2 TibuSURE SSc study is enrolling with topline data expected in H1 2027. The company says cash and cash equivalents are expected to fund planned operations through 2027, covering the anticipated readouts.
Zura Bio (Nasdaq: ZURA) reported third quarter 2025 results and pipeline progress on November 13, 2025. The company reported $139.0 million in cash and cash equivalents as of September 30, 2025, which it expects will fund planned operations through 2027.
Zura continued advancement of two Phase 2 tibulizumab trials: TibuSHIELD (hidradenitis suppurativa) with topline data expected in Q3 2026, and TibuSURE (systemic sclerosis) with topline data expected in Q4 2026. Third-quarter 2025 operating items: R&D $11.9M (vs. $6.0M year-ago), G&A $7.6M (vs. $13.3M year-ago), and net loss $20.0M or $0.21 per share (vs. $22.9M, $0.26 per share).
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Cantor Fitzgerald Global Healthcare Conference. The company's leadership team will engage in a fireside chat on September 4, 2025, at 2:45 PM ET in New York.
The presentation will be accessible via live webcast through the Investors section of Zura Bio's website, with a replay available for at least 30 days. Additionally, the company will conduct one-on-one meetings with investors during the conference.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, reported Q2 2025 financial results and corporate updates. The company initiated TibuSHIELD, a Phase 2 study of tibulizumab for hidradenitis suppurativa, and continued progress on TibuSURE, another Phase 2 study for systemic sclerosis, with data readouts expected in Q3 2026 and Q4 2026 respectively.
Financial highlights include $154.5 million in cash and equivalents as of June 30, 2025, expected to fund operations through 2027. Q2 2025 net loss was $16.0 million ($0.17 per share), compared to $10.3 million in Q2 2024. R&D expenses increased to $8.7 million from $5.5 million year-over-year, while G&A expenses rose to $9.4 million from $6.2 million.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has granted inducement stock options to seven new employees. The company awarded options to purchase up to 890,950 Class A Ordinary Shares, including 672,000 options to newly appointed CFO Eric Hyllengren.
The grants, approved by the Compensation Committee and Board on July 15, 2025, were made outside the company's 2023 Equity Incentive Plan as employment inducements under Nasdaq Rule 5635(c)(4). The options vest 25% initially, followed by quarterly installments of 1/12th of remaining shares, subject to continued employment.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren will succeed Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition.
Hyllengren brings over 20 years of financial leadership experience in life sciences and biotechnology. He previously served as COO and CFO at Atara Biotherapeutics, where he managed strategic finance, capital markets, operational planning, and other key functions. Before that, he spent 15 years at Amgen in various roles including corporate finance, investor relations, and business development.
Badial, who joined Zura Bio in March 2023 during its business combination with JATT Acquisition Corporation, helped develop the company's financial systems and participated in capital-raising initiatives during his tenure.